# Ipamorelin structure and mechanism Canonical: https://europeanpeptideshop.com/blog/ipamorelin-research/ Explore the catalogue and research library. Ordering and shipping have not opened yet. Compound research · 8 November 2026 · 3 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/) ### On this page Ipamorelin is a synthetic pentapeptide with a terminal amide and several modified amino-acid residues. It is studied as a growth-hormone secretagogue acting through the ghrelin-receptor system. Its structure and observed hormone responses are specific research findings, rather than proof of broader body-composition or recovery benefits. [1](https://pubchem.ncbi.nlm.nih.gov/compound/9831659) [2](https://pubmed.ncbi.nlm.nih.gov/9849822/) ## What does the ipamorelin sequence mean? The condensed sequence is H: Aib: His: D-2-Nal: D-Phe: Lys: NH2, read from the amino terminus toward the amidated carboxyl terminus. Aib is alpha-aminoisobutyric acid; D-2-Nal is a naphthylalanine residue. The D prefixes specify stereochemistry and must not be dropped when identifying the material. [1](https://pubchem.ncbi.nlm.nih.gov/compound/9831659) Identity field | Reference ipamorelin Residues | 5 Sequence | Aib: His: D-2-Nal: D-Phe: Lys: NH2 Terminal group | Lys carboxamide Molecular formula | C38H49N9O5 Average molecular weight | 711.9 g/mol PubChem identifier | CID 9831659 [1](https://pubchem.ncbi.nlm.nih.gov/compound/9831659) ## Which receptor pathway is involved? FDA’s scientific assessment describes ipamorelin as a ghrelin mimetic and the ghrelin receptor as a G-protein-coupled receptor. Its signaling includes Gq/11-associated phospholipase activation. [3](https://www.fda.gov/media/182088/download) The original 1998 pharmacology paper used antagonist experiments to distinguish a GHRP-like receptor pathway from the GHRH receptor. Both pathways can be discussed in connection with growth-hormone release, but sharing a downstream hormone response does not make the receptors or ligands identical. [2](https://pubmed.ncbi.nlm.nih.gov/9849822/) This distinction matters when comparing peptide names. A mechanism description should identify the receptor or pathway actually tested, the experimental system and the measured output. A generic phrase such as growth-hormone peptide leaves those details unresolved. ## What did the early selectivity experiments establish? Raun and colleagues examined rat pituitary cells and animal experiments, including hormone measurements in swine. Their selectivity conclusion concerns the comparisons and conditions in those experiments. It should not become an unconditional claim that ipamorelin affects only one hormone in every person or setting. [2](https://pubmed.ncbi.nlm.nih.gov/9849822/) The paper’s title describes a selective secretagogue, but selectivity is a measured relationship between effects under specified conditions. It is not a substitute for a clinical safety study, nor does it verify an outcome for a different formulation or a mixture of compounds. ## What was measured in human pharmacology research? A 1999 study in healthy male volunteers measured ipamorelin concentrations and growth-hormone responses across infusion conditions. The investigators used pharmacokinetic: pharmacodynamic modeling to describe exposure and the time course of hormone release. Its endpoints were drug disposition and GH response, not muscle gain or injury recovery. [4](https://pubmed.ncbi.nlm.nih.gov/10496658/) The reported concentration: response relationship belongs to that study design. It should not be turned into a universal dosing schedule or a duration-of-benefit claim. A measured blood-concentration profile and a clinically meaningful functional outcome are different endpoints. ## How should structure be checked against laboratory documentation? The reference molecular weight above describes the peptide entity. Documentation should separately identify any salt or counterion. PubChem’s explicit residue and terminal notation is more informative than a short name alone when comparing the material used in a paper with a specification. [1](https://pubchem.ncbi.nlm.nih.gov/compound/9831659) Intact molecular mass alone cannot distinguish all amino-acid arrangements or D/L configurations. A purity percentage likewise does not establish sequence, biological potency or the amount of peptide present. Keep those analytical questions separate when reading a certificate, and check whether the methods actually address the claimed identity. ## EPS documentation Use the [research catalogue](https://europeanpeptideshop.com/shop/) to check the exact name, labelled amount and format. The [COA library](https://europeanpeptideshop.com/coa/) publishes the original Janoshik reports selected for EPS, retaining the original report client name and any missing batch fields. Literature findings and another supplier's analytical results are not evidence about an EPS batch. ## Laboratory research only Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here. ## References - [PubChem: Ipamorelin, CID 9831659](https://pubchem.ncbi.nlm.nih.gov/compound/9831659) - [Raun et al., 1998: original ipamorelin pharmacology](https://pubmed.ncbi.nlm.nih.gov/9849822/) - [FDA October 2024 scientific assessment: ipamorelin](https://www.fda.gov/media/182088/download) - [Gobburu et al., 1999: ipamorelin PK/PD in volunteers](https://pubmed.ncbi.nlm.nih.gov/10496658/) ## Related listings [10 mg](https://europeanpeptideshop.com/shop/ipamorelin-10mg/) Growth hormone research ### [Ipamorelin](https://europeanpeptideshop.com/shop/ipamorelin-10mg/) 10 mg · Lyophilised powder Ordering opens later. Prices and availability are not yet published.[Details](https://europeanpeptideshop.com/shop/ipamorelin-10mg/) ## More articles Comparisons · 3 min read ## [Ipamorelin, CJC-1295 and sermorelin](https://europeanpeptideshop.com/blog/ipamorelin-vs-cjc-1295-vs-sermorelin/) How these names differ, why CJC-1295 DAC data cannot be transferred to a no-DAC listing, and what to check in a blended research material. 8 November 2026 Comparisons · 4 min read ## [CJC-1295: DAC, no DAC and blends](https://europeanpeptideshop.com/blog/cjc-1295-dac-no-dac-ipamorelin/) Compare standalone CJC-1295 with DAC, no DAC and Ipamorelin with a two-ingredient blend. Check the exact listing, component amounts and report. 8 November 2026 Documentation · 3 min read ## [Peptide storage records](https://europeanpeptideshop.com/blog/peptide-storage-records/) Start with the exact material and its documentation. A useful storage record preserves what was known at receipt and what happened afterwards. 8 November 2026